Tatva Chintan Pharma Chem · tone and specificity signals across the available quarters.
Language signals
We have kept ourselves largely away from conventional chemistry and focused largely on catalytic or electrolytic chemistries and I think that strategy is paying off. So we can bring a real winning situation for the customer as well and still sustain our margins.
The kind of geopolitical situations that keep coming up, number of factors which are currently impacting globally... would have impact on the global economy for sure but despite of this we are excited with what we have done, what is there on the plate for us and we are not stopping with any of our ongoing plans.
Most of it has gone towards utilization expansion so basically we have observed lot of bottlenecks in terms of handling the product, moving the product, certain missing blocks in production which we are not able to reuse the byproducts so we are trying to optimize the profit.
We have already maintained that we will be growing the revenue by around 25%. And EBITDA should be in range of somewhere around 20 to 22%. On a very realistic basis so we'll stick to that.
The increased prices have gradually been implemented on new orders. With multiple developments getting into commercial phase, we foresee the momentum of growth to continue for next two years. Once the new greenfield project at Dahej goes online, it will bring in the next phase of growth from financial year 28-29.
We are also witnessing improved customer engagement across key geographies with business discussions becoming more structured. Given the specialized nature of this chemistry and our established position in the segment, we continue to remain positive on the long-term prospects of the SDA business.